Soleno STarts Study of DCCR for Treatment of Prader-Willi Syndrome

 Soleno Therapeutics , Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated a randomized withdrawal period of Study C602, an ongoing open-label extension study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS).

https://www.biospace.com/article/releases/soleno-therapeutics-announces-initiation-of-randomized-withdrawal-study-of-dccr-for-the-treatment-of-prader-willi-syndrome/